5. Shi Y, et al.Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small c...
[3]Shi Y, Chen G, Wang X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a...
[6]Park K, Tan EH, OByrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology. 2016;17(5):577-589. [7]Ramalingam S S,...
S.; Tsuji, F.; Linke, R.; Rosell, R.; Corral, J.; et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): Arandomised, open-label, phase 3 trial. Lancet Oncol. 2017, 18, 1454–1466. ...
[7]Shi Y, Chen G, Wang X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study[J]. Lancet Respir ...
1. EGFR mutation subtypes and response to immunecheckpoint blockade treatment in non-small cell lung cancer.Ann Oncol.2019 May 14. pii: mdz141.2. Tumor immune microenvironment and nivolumab efficacyin EGFR mutation-positive non-small-cell lung cancer based on T790M statusafter disease progression ...
[4] GELATTI A C Z,DRILON A,SANTINI F C. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor ( EGFR) mutation-positive non-small cell lung cancer (NSCLC)[J]. Lung Cancer,2019,137: 113 - 122. ...
[1] Hamaguchi R,etal. Effects of anAlkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC. Anticancer Res. 2017Sep;37(9):5141-5145.[2] Hao Y, et al.Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective...
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol (2020) 21(3):373–86. doi: 10.1016/S1470-2045(...
EGFR突变肺癌靶向耐药后出现BRAF突变，三靶治疗？EGFR（epidermal growth factor receptor, 表皮生长因子受体）突变是非小细胞肺癌（non-small cell lung cancer, NSCLC）中最常见的驱动基因，高达50%以上的东亚患者存在该突变[1]。EGFR抑制剂（EGFR TKI）治疗对EGFR突变的晚期NSCLC患者与化疗相比具有更好的疗效[2]。...